Work

A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-160039

Authors: Haris Ali, Ashwin Kishtagari, Keri Maher, Sanjay R Mohan, Karen Ansaldo, Xulong Wang, Kamal Chamoun, Josef T. Prchal, Srinivas K. Tantravahi

Institutions: City Of Hope National Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Virginia Commonwealth University, Karyopharm Therapeutics (United States), University of Utah, Huntsman Cancer Institute

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310089971

FWCI: 0.62

Cites:

Cited by: 4

Related to: 10